Kimberly Hindi
General Practice · Montgomery, ALNPI 1043221161
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,184 and has fallen 53.7% since, to $548 in 2025. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$782
- Lilly USA, LLC$601
- GSK$596
- Amgen$383
- Abbott$334
- Pfizer$207
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,129100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $782 |
| Lilly USA, LLC | 42 | $601 |
| GSK | 31 | $596 |
| Amgen | 21 | $383 |
| Abbott | 17 | $334 |
| Pfizer | 11 | $207 |
| AbbVie | 10 | $192 |
| Boehringer Ingelheim | 11 | $178 |
| AstraZeneca | 9 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $159 |
| Merck | 4 | $75 |
| Exact Sciences | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $68 |
| Regeneron Healthcare Solutions, Inc. | 1 | $61 |
| Johnson & Johnson | 3 | $53 |
| Mylan Specialty L.p. | 2 | $35 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
How this compares
$4,141 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 118 | $148,778 |
| OzempicSemaglutide | 120 | $140,949 |
| JardianceEmpagliflozin | 66 | $70,232 |
| JanuviaSitagliptin Phosphate | 64 | $52,794 |
| TrulicityDulaglutide | 44 | $51,841 |
| FarxigaDapagliflozin Propanediol | 38 | $38,309 |
| CreonLipase/Protease/Amylase | 33 | $32,483 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $32,003 |
| EliquisApixaban | 35 | $28,598 |
| LinzessLinaclotide | 20 | $19,237 |
| XareltoRivaroxaban | 20 | $18,620 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $16,807 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $16,514 |
| GemtesaVibegron | 23 | $16,199 |
| MyrbetriqMirabegron | 17 | $15,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $601 | $200,620162 claims |
| Novo NordiskOzempic | $782 | $140,949120 claims |
| Boehringer IngelheimJardiance, Tradjenta | $178 | $77,77979 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $596 | $65,324115 claims |
| AbbVieCreon, Linzess, Synthroid | $192 | $54,38082 claims |
| MerckJanuvia | $75 | $52,79464 claims |
| AstraZenecaFarxiga | $176 | $38,30938 claims |
| PfizerEliquis | $207 | $28,59835 claims |
| Johnson & JohnsonXarelto | $53 | $18,62020 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $15,94917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.
Other general practice in Montgomery
- Bradley WillisMontgomery$151K
- Ashley McIntyreMontgomery$123K
- Samuel McLemoreMontgomery$4K
- Frank TombrelloBirmingham$163K
- John BurgessBirmingham$117K
- Glenn HarnettHoover$113K
- Alan ColemanAthens$30K
- Darrell DoucetteHuntsville$20K
- Earl RogersMobile$19K
- Jennifer DoobrowCullman$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.